ArriVent BioPharma (AVBP) moved into focus after announcing a Collaboration and License Agreement with Shanghai Allist Pharmaceuticals covering ARR-002 in Greater China, alongside new second-quarter and first-half 2026 earnings figures.

ArriVent BioPharma’s recent 10.93% 1-day share price return to US$31.35, following the Allist agreement and earnings update, comes after a softer 1-month share price return of a 1.20% decline. However, the 90-day share price return of 14.12% and 60.03% 1-year total shareholder return indicate that momentum has been building over a longer period.

Compare ArriVent BioPharma's latest move with other potential breakout biopharma opportunities and scan a curated 18 high quality undiscovered gems that share strong fundamentals and under-the-radar potential.

After ArriVent BioPharma’s sharp move and fresh Allist deal, the stock still trades at a sizeable discount to analyst targets and an estimated intrinsic value. Is that a mispricing, or a fair reflection of clinical and earnings risk?

Price to Book of 4.2x for ArriVent BioPharma: Is it justified?

On a preferred multiple basis, ArriVent BioPharma trades on a P/B of 4.2x, which sits above the broader US Biotechs industry average of 2.5x and reflects a richer valuation than many sector peers.

P/B compares the market value of a company to its net assets. For a clinical stage biotech like ArriVent BioPharma with no revenue yet and a reported net loss of $164.21m, investors often focus on this ratio to gauge how much is being paid for the pipeline, partnerships, and cash on the balance sheet relative to the underlying book value.

The 4.2x P/B is described as expensive relative to the wider US Biotechs industry. However, compared to a closer peer group where the average P/B is 7.5x, ArriVent BioPharma is assessed as good value on the same metric. The stock is also flagged as trading at a sizeable discount to an internal estimate of future cash flow value of $69.10 per share and at a 54.6% discount to that fair value, which introduces a different angle than the headline multiple.

Result: Price-to-book of 4.2x (ABOUT RIGHT).

However, ArriVent BioPharma’s story still depends on successful trial outcomes for firmonertinib and other pipeline assets, as well as access to fresh funding given its reported loss.

Another View on ArriVent BioPharma’s Valuation

The earlier discussion focused on ArriVent BioPharma’s 4.2x P/B against industry and peer benchmarks. A second lens comes from the SWS DCF model, which estimates future cash flow value at $69.10 per share versus the current $31.35. That implies the stock trades at a 54.6% discount. This raises a key question: Is the market underestimating the pipeline, or are analysts too optimistic on future cash flows?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out ArriVent BioPharma for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 49 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

If the mixed signals around ArriVent BioPharma leave you unsure, now is the time to review the data closely and decide where you stand. To weigh the upside potential against the concerns investors have flagged, start with the 3 key rewards and 3 important warning signs.

Looking for more investment ideas beyond ArriVent BioPharma?

If ArriVent BioPharma has sharpened your focus, you can use this momentum to scan fresh ideas now so you do not miss the next opportunity building under the surface.

• Target stability first and check out a curated 74 resilient stocks with low risk scores that may suit you if you prefer companies with steadier risk profiles.
• Hunt for quality at a potential discount by reviewing a focused 49 high quality undervalued stocks that filters for fundamentals that many investors watch closely.
• Strengthen your watchlist with financially healthier businesses by scanning a list of solid balance sheet and fundamentals (51 results) that highlights stronger balance sheets and underlying resilience.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.